Skip to content

On this page

Tysabri

natalizumab

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Tysabri

Proper name

natalizumab

Licence type

351(a)

BLA number

125104

Applicant

Biogen Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
300MG/15ML (20MG/ML)	Injection	Intravenous	Single-Dose Vial	Rx	November 23, 2004

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity